Delcath Systems (NASDAQ:DCTH) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $22.00 target price on the stock.

DCTH has been the topic of several other reports. Canaccord Genuity Group restated a “buy” rating and set a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. Stephens restated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Delcath Systems Stock Down 0.8 %

NASDAQ DCTH opened at $12.69 on Tuesday. The firm has a market capitalization of $405.75 million, a price-to-earnings ratio of -9.40 and a beta of 0.87. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $13.30. The company has a fifty day moving average of $11.33 and a two-hundred day moving average of $9.83.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Delcath Systems in the third quarter worth approximately $102,000. Barclays PLC acquired a new position in shares of Delcath Systems in the 3rd quarter valued at $104,000. Jane Street Group LLC acquired a new position in shares of Delcath Systems in the 3rd quarter valued at $110,000. Riverwater Partners LLC purchased a new position in shares of Delcath Systems during the 3rd quarter worth $161,000. Finally, Virtu Financial LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth about $289,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.